Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;81(1):76-90.
doi: 10.1016/j.jaad.2019.02.067. Epub 2019 Mar 11.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management

Ali Alikhan  1 , Christopher Sayed  2 , Afsaneh Alavi  3 , Raed Alhusayen  3 , Alain Brassard  4 , Craig Burkhart  5 , Karen Crowell  6 , Daniel B Eisen  4 , Alice B Gottlieb  7 , Iltefat Hamzavi  8 , Paul G Hazen  9 , Tara Jaleel  10 , Alexa B Kimball  11 , Joslyn Kirby  12 , Michelle A Lowes  13 , Robert Micheletti  14 , Angela Miller  8 , Haley B Naik  15 , Dennis Orgill  16 , Yves Poulin  17
Affiliations
Review

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management

Ali Alikhan et al. J Am Acad Dermatol. 2019 Jul.

Abstract

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.

Keywords: Nd:YAG; acne inversa; adalimumab; biomarkers; carbon dioxide laser; clindamycin; comorbidities; ertapenem; finasteride; guidelines; hidradenitis suppurativa; infliximab; laser; lifestyle modification; microbiome; oral contraceptive pills; rifampin; spironolactone.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Dr Sayed reports service as a speaker for AbbVie and Novartis, an advisory board member for AbbVie and InflaRx, a coinvestigator for AbbVie and Novartis, and an investigator for InflaR and UCB. Dr Hamzavi reports service as an investigator for AbbVie, The Microdermis Corporation, Adelphi Values, and Lenicura and a consultant for UCB and Incyte; in addition, he is president of the Hidradenitis Suppurativa Foundation. Dr Hazen reports service as a speaker for AbbVie and an advisory board member for AbbVie. Dr Kimball reports service as a consultant and investigator for Amgen, AbbVie, Janssen, and Novartis and has received fellowship funding from Novarti and AbbVie. Dr Lowes reports service as an advisory board member for AbbVie and Janssen and a consultant for AbbVie, XBiotech, and Incyte. Dr Alavi reports service as a clinical investigator and consultant for AbbVie, Janssen, Novartis, Pfizer, Galderma, Leo, and Valeant and has received grant funding from AbbVie. Dr Naik reports grant funding from AbbVie. Dr Alhusayen reports service for AbbVie as an advisory board member and consulting and has received research funding from the company; he has also served as an advisory board member for Janssen and a consultant for Eli Lilly and Company and Hidramed Solutions. Dr Orgill has served as a consultant and investigator for KCI, Inc, and Integra. Dr Brassard has served as a speaker and advisory board member for AbbVie, Janssen, Celgene, and 3M and as a speaker for Coloplast and Hollister. Dr Miller has served as a consultant for AbbVie and an advisory board member for AbbVie and BSN; in addition, she is employed by the Hidradenitis Suppurativa Foundation and is president and founding director of the Hope for HS support group. Dr Poulin has served as an investigator, advisory board member, and speaker for AbbVie. Dr Kirby has served as an advisory board member and speaker for AbbVie and a consultant for Incyte and Chemocentryx. Dr Gottlieb has served as an investigator for Novartis and a speaker for AbbVie. Dr Jaleel has served as an investigator for Eli Lilly and Company. Dr Alikhan, Dr Micheletti, Dr Eisen, Dr Burkhart, and Dr Crowell have no conflicts of interest to disclose.

Comment in

References

    1. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398. - PubMed
    1. Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994. - PMC - PubMed
    1. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501–504. - PubMed
    1. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217. - PubMed
    1. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–974. - PubMed